<DOC>
	<DOC>NCT01283958</DOC>
	<brief_summary>Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.</brief_summary>
	<brief_title>The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Defects, Congenital</mesh_term>
	<mesh_term>Eisenmenger Complex</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Iloprost, Eisenmenger's syndrome</keyword>
</DOC>